Barclays PLC vs TransMedics Group Inc — how do they compare? Barclays PLC trades at $28.12 (market cap $93.87B), while TransMedics Group Inc trades at $87.18 (market cap $3.10B). The key difference: Barclays PLC is far larger — about 30.3× TransMedics Group Inc's market cap, and Barclays PLC pays a 2.19% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| BCS | TMDX | |
|---|---|---|
Market Cap | $93.87B | $3.10B |
Sector | Financials | Technology |
52-Week High | $28.56 | $150.42 |
52-Week Low | $19.36 | $61.99 |
Dividend Yield | 2.19% | — |
Enterprise Value | — | $3.49B |
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $28.08, up 0.36% today, with a bullish technical signal from moving averages and a P/B ratio below 1 at 0.88, indicating potential undervaluation. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.90 surpassing the $0.89 estimate, while revenue growth accelerated to $29.14 billion in 2025. However, the stock faces headwinds from a securities class action investigation and concerns over cost pressures highlighted in recent analyst reports.
The outlook for BCS is cautiously optimistic, supported by strong profitability with a net income margin of 25.51% and analyst consensus favoring Buy ratings (68%). Key risks include ongoing legal scrutiny and rising operating expenses, but the stock's low valuation and dividend yield near 1.1% offer value for long-term investors amid stable cash flow trends.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Trailing returns across standard periods
Latest headlines on both assets
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →